Exclusive License and Collaboration AgreementExclusive License and Collaboration Agreement • June 5th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT IS ENTERED INTO EFFECTIVE AS OF AUGUST 06, 2012 (THE ‘‘EFFECTIVE DATE”) BETWEEN:
CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A...Finance Contract • June 5th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations
Amendment #1 to the Exclusive License and Collaboration AgreementExclusive License and Collaboration Agreement • June 5th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations
AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • June 5th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations • Texas
Contract number (FI No): 89427 Contract number (FI No): 89987 Serapis No: 2018-0245 European Investment Bank (the Bank) - and - Nanobiotix (the Company) Royalty Agreement Matter ref 1M0186.000509 PAARB/1864409 Hogan Lovells (Paris) LLP 17 avenue...Royalty Agreement • June 5th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations
